Breast Cancer

75 competing products in clinical development for Breast Cancer.

Pipeline by Phase

Pre-clinical2

Phase 116

Phase 1/25

Phase 230

Phase 321

Approved1

All Products (75)

Product	Company	Stage	Status	Hype
Dato-DXd + Durvalumab + Paclitaxel + Nab-paclitaxel + Gemcitabine + Carboplatin + Pembrolizumab	Daiichi Sankyo	Phase 3	Recruiting	47
Dato-DXd	Daiichi Sankyo	Phase 3	Recruiting	47
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 3	Recruiting	47
pegylated liposomal doxorubicin (PLD) + cyclophosphamide (C) + trastuzumab (H) + pertuzumab (P) + docetaxel (T) + docetaxel (T) + carboplatin (Cb) + trastuzumab (H) + pertuzumab (P)	Sun Pharmaceutical	Phase 3	Recruiting	47
Paclitaxel + bevacizumab therapy + Paclitaxel + bevacizumab + atezolizumab	Chugai Pharmaceutical	Phase 3	Active	44
Dato-DXd + Capecitabine + Gemcitabine + Eribulin + Vinorelbine	Daiichi Sankyo	Phase 3	Active	44
Trastuzumab Deruxtecan	Daiichi Sankyo	Phase 3	Active	44
Trastuzumab deruxtecan (DS-8201a) + Capecitabine + Eribulin + Gemcitabine + Paclitaxel + Nab-paclitaxel	Daiichi Sankyo	Phase 3	Active	44
Dato-DXd + Durvalumab + Pembrolizumab + Doxorubicin + Epirubicin + Cyclophosphamide + Paclitaxel + Carboplatin + Capecitabine + Olaparib	Daiichi Sankyo	Phase 3	Active	44
Trastuzumab deruxtecan (T-DXd) + Ado-trastuzumab emtansine (T-DM1)	Daiichi Sankyo	Phase 3	Active	44
Dato-DXd + Durvalumab + Capecitabine + Pembrolizumab	Daiichi Sankyo	Phase 3	Active	44
Dato-DXd + Paclitaxel + Nab-paclitaxel + Carboplatin + Capecitabine + Eribulin mesylate	Daiichi Sankyo	Phase 3	Active	44
arzoxifene	Eli Lilly	Approved	Completed	43
Datopotamab Deruxtecan	Daiichi Sankyo	Phase 2	Recruiting	42
Lenvatinib + Letrozole + Fulvestrant	Eisai	Phase 2	Recruiting	42
gemcitabine hydrochloride + paclitaxel	Eli Lilly	Phase 3	Completed	40
Atezolizumab + Placebo + Doxorubicin + Cyclophosphamide + Paclitaxel + Trastuzumab + Pertuzumab + Trastuzumab Emtansine	Chugai Pharmaceutical	Phase 3	Completed	40
Trastuzumab deruxtecan + Capecitabine + Lapatinib + Trastuzumab	Daiichi Sankyo	Phase 3	Completed	40
Pertuzumab + Trastuzumab + Docetaxel + Paclitaxel + Eribulin	Eisai	Phase 3	Completed	40
E7389 + Physician's Choice	Eisai	Phase 3	Completed	40
VS-6766 + Abemaciclib + Fulvestrant	Eli Lilly	Phase 1/2	Recruiting	39
Trastuzumab-Deruxtecan (T-DXd)	Daiichi Sankyo	Phase 2	Active	39
Patritumab deruxtecan + Chemotherapy + Letrozole	Daiichi Sankyo	Phase 2	Active	39
Enzalutamide	Astellas Pharma	Phase 2	Active	39
PTC-Pz	Roche	Phase 2	Active	39
BB-1701	Eisai	Phase 2	Active	39
Lenvatinib + Letrozole	Eisai	Phase 1/2	Active	36
gemcitabine + paclitaxel + bevacizumab	Eli Lilly	Phase 2	Completed	35
Gemcitabine + Adriamycine + Paclitaxel	Eli Lilly	Phase 2	Completed	35
gemcitabine + vinorelbine	Eli Lilly	Phase 2	Completed	35
pemetrexed + cyclophosphamide + doxorubicin + docetaxel	Eli Lilly	Phase 2	Completed	35
pemetrexed + gemcitabine	Eli Lilly	Phase 2	Completed	35
pemetrexed	Eli Lilly	Phase 2	Completed	35
exatecan mesylate	Daiichi Sankyo	Phase 2	Completed	35
Abraxane alone + Abraxane + Tigatuzumab	Daiichi Sankyo	Phase 2	Completed	35
Enzalutamide + exemestane + Placebo (for enzalutamide) + exemestane	Astellas Pharma	Phase 2	Completed	35
YM155 + Docetaxel	Astellas Pharma	Phase 2	Completed	35
Eribulin Mesylate + Ixabepilone	Eisai	Phase 2	Completed	35
Eribulin Mesylate	Eisai	Phase 2	Completed	35
Paclitaxel + Eribulin + 5-Fluorouracil + Epirubicin + Cyclophosphamide + Doxorubicin	Eisai	Phase 2	Completed	35
Eribulin Mesylate	Eisai	Phase 2	Completed	35
E7389	Eisai	Phase 2	Completed	35
Paclitaxel + Eribulin + Doxorubicin + Cyclophosphamide	Eisai	Phase 2	Completed	35
Eribulin Mesylate	Eisai	Phase 2	Completed	35
Eribulin	Eisai	Phase 2	Completed	35
Trastuzumab deruxtecan (DS-8201a) + Trastuzumab deruxtecan (DS-8201a) + Pembrolizumab	Daiichi Sankyo	Phase 1	Active	33
Trastuzumab deruxtecan + Valemetostat	Daiichi Sankyo	Phase 1	Active	33
monoclonal antibody CAL + zoledronic acid	Chugai Pharmaceutical	Phase 1/2	Completed	32
Placebo + Denosumab	Daiichi Sankyo	Phase 3	Terminated	32
Enzalutamide + Placebo + Paclitaxel	Astellas Pharma	Phase 3	Withdrawn	32
lenvatinib	Eisai	Phase 2	UNKNOWN	31
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	Completed	30
Lymphoseek	Navidea Biopharmaceuticals	Phase 3	Completed	30
Biomarkers blood, urine and microbiota samples	Eli Lilly	Pre-clinical	Active	30
Trastuzumab deruxtecan + Nivolumab	Daiichi Sankyo	Phase 1	Completed	29
enzalutamide + anastrozole + exemestane + fulvestrant + enzalutamide + exemestane	Astellas Pharma	Phase 1	Completed	29
Metformin + Erlotinib	Astellas Pharma	Phase 1	Completed	29
Eribulin + Carboplatin	Eisai	Phase 1	Completed	29
Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)	Eisai	Phase 1	Completed	29
E7389	Eisai	Phase 1	Completed	29
KHK2375 + Exemestane	Kyowa Kirin	Phase 1	Completed	29
Experimental Arm A: Pemetrexed + Experimental Arm A: Sorafenib + Experimental Arm B: Pemetrexed + Experimental Arm B: Sorafenib	Eli Lilly	Phase 2	Terminated	27
DS-8201a	Daiichi Sankyo	Phase 2	Terminated	27
Filgrastim + Peg-filgrastim	Kyowa Kirin	Phase 2	Terminated	27
Intratumoral Mitazalimab + Intratumoral Nivolumab	Alligator Bioscience AB	Phase 1	Recruiting	26
Azenosertib + Carboplatin + Pembrolizumab	Zentalis Pharmaceuticals	Phase 1/2	Active	26
BBI-940 + Fulvestrant	Boundless Bio	Phase 1	Recruiting	26
Eribulin Mesylate	Eisai	Pre-clinical	Completed	26
Alpelisib + Tamoxifen + Zotatifin + Fulvestrant	eFFECTOR Therapeutics	Phase 2	Completed	25
U3 1402 + U3 1402	Daiichi Sankyo	Phase 1	UNKNOWN	25
Doxorubicin Hydrochloride Liposome Injection	Sun Pharmaceutical	Phase 1	UNKNOWN	25
Decitabine, LBH589, Tamoxifen	Eisai	Phase 1/2	Terminated	24
KW-2450 in combination with lapatinib and letrozole	Kyowa Kirin	Phase 1	Terminated	21
tomivosertib + paclitaxel	eFFECTOR Therapeutics	Phase 1	Completed	19
Pelareorep + Letrozole + Atezolizumab + Trastuzumab	Biotech Research Group	Phase 1	Terminated	11